The new vaccine program, named EVX-B4, has been added to Evaxion’s research & development (R&D) pipeline of cancer and infectious disease vaccine candidates. Deploying AI-Immunology allows for fast and effective target discovery, design and validation, accelerating preclinical development of EVX-B4, states the company. This work will create a comprehensive preclinical data package to facilitate partnership discussions, it states further.

“We are excited to add EVX-B4 to our R&D pipeline following an extensive evaluation of numerous bacterial pathogens causing severe medical complications, and for which no preventive vaccine exists. With guidance from a panel of world-renowned experts, we prioritized GAS as a key target where our AI-Immunology™ platform could provide substantial benefit. The urgent need for options to prevent GAS infections is huge, underscoring the significant medical and commercial potential of EVX-B4 as well as multiple partnering options,” says Birgitte Rønø, CSO of Evaxion.

Evaxion’s R&D pipeline now comprises five specified vaccine candidates for infectious diseases and three for cancer.